Samuel M. Moskowitz
Vertex Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Cystic Fibrosis Research Advances, Bacterial biofilms and quorum sensing, Antibiotic Resistance in Bacteria, Neonatal Respiratory Health Research, Bacterial Genetics and Biotechnology
Most-Cited Works
- → Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele(2019)2,037 cited
- → Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients(2006)1,343 cited
- → Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial(2019)1,322 cited
- → VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles(2018)717 cited
- → PmrAB, a Two-Component Regulatory System of Pseudomonas aeruginosa That Modulates Resistance to Cationic Antimicrobial Peptides and Addition of Aminoarabinose to Lipid A(2003)410 cited
- → Clinically Feasible Biofilm Susceptibility Assay for Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis(2004)391 cited
- → Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control(2017)370 cited
- → VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles(2018)323 cited
- → A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele(2021)272 cited
- → Triple Therapy for Cystic Fibrosis Phe508del –Gating and –Residual Function Genotypes(2021)263 cited